当前位置: 首页 >> 检索结果
326. Donor-Derived Epstein-Barr Virus Infection Among Pediatric Kidney Transplant Recipients.
作者: Vishnu S Potluri.;Sandra Amaral.;Chethan M Puttarajappa.;Siqi Zhang.;Kaitlin J Devine.;Peter P Reese.;Elizabeth M Sonnenberg.
来源: JAMA. 2025年334卷16期1482-1484页 328. Everolimus and Low-Dose Tacrolimus After Heart Transplant in Children: A Randomized Clinical Trial.
作者: Christopher S Almond.;Kevin P Daly.;Erin L Albers.;Juan C Alejos.;Rebecca Ameduri.;Scott R Auerbach.;Lynsey Barkoff.;Aliessa P Barnes.;Matthew J Bock.;Arene Butto.;Waldemar F Carlo.;Chesney D Castleberry.;Maryanne R Chrisant.;Shriprasad R Deshpande.;William J Dreyer.;Melanie D Everitt.;Brian Feingold.;Selena Gonzales.;Seth A Hollander.;Steven J Kindel.;Gloria L Klein.;Ashwin K Lal.;Jacqueline M Lamour.;Joanne Lee.;Minmin Lu.;Irene D Lytrivi.;Shelley D Miyamoto.;Elfriede Pahl.;David M Peng.;Thomas D Ryan.;Tajinder P Singh.;Jennifer A Su.;David L Sutcliffe.;A Marian Ybarra.;Steven Zangwill.;Joseph W Rossano.;Lynn A Sleeper.; .
来源: JAMA. 2025年334卷15期1339-1348页
Studies suggest that everolimus may reduce the risk of rejection, cardiac allograft vasculopathy (CAV), chronic kidney disease (CKD), and cytomegalovirus (CMV) after heart transplant. Everolimus use is controversial because of data demonstrating higher infection deaths when everolimus is introduced de novo after transplant. It is unclear whether everolimus is safe and effective when initiated at 6 months posttransplant in children, a population in which median graft survival is limited to 15 years and randomized clinical trials are lacking.
334. Individualized Prediction of Platelet Transfusion Outcomes in Preterm Infants With Severe Thrombocytopenia.
作者: Hilde van der Staaij.;Ilaria Prosepe.;Camila Caram-Deelder.;Ruth H Keogh.;Emöke Deschmann.;Christof Dame.;Wes Onland.;Sandra A Prins.;Florian Cassel.;Esther J d'Haens.;Elke van Westering-Kroon.;Peter Andriessen.;Sabine L Vrancken.;Christian V Hulzebos.;Daniel C Vijlbrief.;Suzanne F Fustolo-Gunnink.;Karin Fijnvandraat.;Enrico Lopriore.;Johanna G van der Bom.;Nan van Geloven.
来源: JAMA. 2025年334卷14期1267-1277页
Preterm infants with severe thrombocytopenia (platelet count <50 × 109/L) frequently receive platelet transfusions. However, it is unclear in what cases prophylactic transfusion truly reduces bleeding risk or whether it does more harm than good.
337. Superficial Vein Thrombosis: A Review.
作者: Gregory Piazza.;Darsiya Krishnathasan.;Nada Hamade.;Francisco Ujueta.;Giovanni Scimeca.;Marcos D Ortiz-Rios.;Bridget McGonagle.;Jean-Philippe Galanaud.;David Jiménez.;Manuel Monreal.;John Fanikos.;Anahita Dua.;Leben Tefera.;Raghu Kolluri.;Sahil A Parikh.;Walter Ageno.;Samuel Z Goldhaber.;Jeffrey I Weitz.;Lisa K Moores.;Isabelle Quéré.;Behnood Bikdeli.
来源: JAMA. 2025年
Superficial vein thrombosis (SuVT) is characterized by thrombus in the superficial veins, typically in the lower or upper extremities, and has an estimated annual incidence of 64 to 131 per 100 000 person-years. Approximately 10% of patients with SuVT progress to deep vein thrombosis (DVT) or pulmonary embolism (PE).
|